Premature babies treated with an enteral emulsion containing enteral docosahexaenoic acid (DHA) were not at lower risk for physiological bronchopulmonary dysplasia, according to Physician’s Briefing.
The researchers found that 49.1 percent of the 592 infants assigned to the DHA group and 43.9 percent of the 613 assigned to the control group were classified as having physiological bronchopulmonary dysplasia (relative risk adjusted for randomization strata, 1.13). The composite outcome of physiological bronchopulmonary dysplasia or death before 36 weeks of postmenstrual age occurred in 52.3 and 46.4 percent of the infants in the DHA and control groups, respectively (adjusted relative risk, 1.11).
“Enteral DHA supplementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physiological bronchopulmonary dysplasia than a control emulsion among preterm infants born before 29 weeks of gestation and may have resulted in a greater risk,” the authors write.
Get the whole story at www.physiciansbriefing.com
